Silence Therapeutics logo

Silence Therapeutics

SLN | NASDAQ
Chart Builder DCF Calculator
$19.80
-$0.03 (-0.15%)
At close: Nov 16, 2026, 4:00 PM ET
$19.72
-$0.08 (-0.42%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.15%

Rating

Updated: Nov 16, 2026
29.5
-3.0 pts
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #821/1021 (Top 80%)

Key Statistics

Market Data

Market Cap $1.09B
1D Range
19.80 19.83
52W Range
4.30 19.83

Valuation (TTM)

PE -7.25
PB 5.08
EV/EBITDA -16.28

Valuation (NTM)

Forward PE N/A
Forward PEG 0.12
Price Target $20.00
Loading financial charts...

Profile

Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas inc...

Sector Healthcare
Industry Biotechnology
Employees 88
IPO Date Sep 8, 2020
Fiscal Year January - December

Latest News

Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results

4 days ago · businesswire.com

Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026

13 days ago · businesswire.com

Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?

28 days ago · gurufocus.com

Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?

28 days ago · zacks.com

Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)

28 days ago · globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)
Silence Therapeutics jumps 59% on Merck takeover

29 days ago · proactiveinvestors.com

Silence Therapeutics jumps 59% on Merck takeover
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

29 days ago · benzinga.com

Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders

29 days ago · businesswire.com

SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

29 days ago · wsj.com

Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

Earnings

Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Hold
Price Target
$20.00
Upside
+1.01%
Buy (1)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.